BeiGene has decided to end the clinical development program for ociperlimab (BGB-A1217) as a treatment for lung cancer.

An independent data monitoring board found that BeiGene’s ociperlimab was unlikely to significantly boost overall survival in ...

TIGIT, in particular, has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody vibostolimab ...

BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.

BeiGene is ending development of its experimental lung-cancer treatment ociperlimab following the failure of a late-stage study. BeiGene on Thursday said it is stopping a Phase 3 trial of ociperlimab ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...

March 31, 2025--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ ... treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC). "The aggressive nature of extensive-stage small ...

ADRs came under pressure in the premarket on Thursday after the company announced its decision to halt a clinical program targeting its antibody therapy ociperlimab (BGB-A1217) in lung cancer in ...

BeiGene (NASDAQ:ONC ... a clinical program targeting its antibody therapy ociperlimab (BGB-A1217) in lung cancer in reaction to disappointing safety and efficacy data. The cancer drug developer ...